Submitted by Anonymous (not verified) on 12 July 2024 - 15:10
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 6, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 6, Status: Authorised